Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia

Core Insights - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [2][4] - The company recently announced the recommended Phase 2 dose selection for its first-in-class Logic Gated off-the-shelf CAR-NK cell therapy, SENTI-202, aimed at treating relapsed/refractory hematologic malignancies, including acute myeloid leukemia (AML) [3] Company Overview - Senti Bio is leveraging synthetic biology to engineer Gene Circuits that enhance precision and control in new medicines, specifically targeting cancer cells while sparing healthy cells [4] - The company's pipeline includes cell therapies designed to address challenging liquid and solid tumor indications, with preclinical evidence supporting the efficacy of Gene Circuits in both NK and T cells [4] Recent Developments - The participation in the Virtual Investor segment highlights the company's ongoing efforts to communicate its advancements and strategies to potential investors [2][3] - The focus on SENTI-202 represents a significant step in Senti Bio's clinical development, indicating progress in its research and development initiatives [3]